OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members Appointments bring global leadership experience and expertise in drug discovery, as well as clinical
Read more· On June 16 2021, the Company signed a scientific cooperation agreement with the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) in the field of discovery and development of small molecule drugs modulating
Read moreA new publication about the discovery and preclinical characterization of OATD-01, authored by the scientists from OncoArendi Therapeutics, has just been accepted by the Journal of Medicinal Chemistry (J. Med. Chem). OATD-01 is a first-in-class chitinase
Read moreA new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship, including case study of #OncoArendi Therapeutics authored by Marcin Szumowski A new series of
Read moreOncoArendi has recently hired dr. Rafał Kamiński for the position of Chief Scientific Officer. He has acquired broad international experience in discovery and development of innovative small molecule drugs and management of scientific teams from previous
Read moreData presented at the European Society of Medical Oncology (ESMO) in Barcelona by Calithera Biosciences, a biotechnology company from California, USA, add to a growing body of evidence indicating that arginase inhibitors could emerge as novel
Read moreHealthy volunteers study initiated for OATD-01, an innovative therapy for the treatment of asthma Warsaw, Poland, October 9, 2017 - OncoArendi Therapeutics announced today that this week the Company will initiate a Phase 1 study designed
Read moreOATD-01 is a non-steroidal small molecule inhibitor, which has shown excellent pharmacokinetic properties in three species after oral dosing, and the overall DMPK profile that is consistent with the targeted once-a-day oral dosing in humans. OATD-01
Read moreWarsaw, Poland, June 21, 2017 / B3C newswire / -- During the first Company Presentation at the global BIO Conference in San Diego OncoArendi Therapeutics SA announced that it has selected OATD‑02 as its clinical development candidate
Read more
